Trigeminal neuralgia (TN) is considered to be one of the most painful afflictions known to medical practice. TN is a disorder of the fifth cranial (trigeminal) nerve. The typical or “classic” form of the disorder (called TN1) causes extreme, sporadic, sudden burning or shock-like facial pain in the areas of the face where the branches of the nerve are distributed – lips, eyes, nose, scalp, forehead, upper jaw, and lower jaw. The pain episodes last from a few seconds to as long as two minutes. It is hard to dismiss as insignificant the observations made by numerous neurosurgeons during decompressive surgery that arterial compression of the root at the dorsal root entry zone is the common finding in typical TGN. Similarly, in MS patients suffering from TGN, a common finding is the plaque extending into the dorsal root entry zone.The dorsal root entry zone represents the junction between the peripheral and central myelins of Schwann cells and astrocytes. The central branches of the unipolar ganglion cells enter the pons through this transition zone on their course toward the brainstem and spinal nuclei. Patients may find immediate and satisfying relief with one medication, typically carbamazepine. However, because this disorder may remit spontaneously after 6-12 months, patients may elect to discontinue their medication in the first year following the diagnosis. Most must restart medication in the future. Furthermore, over the years, they may require a second or third drug to control breakthrough episodes and finally may need surgical intervention. Spain people around 258,004 among the total population are suffering from this disease that is 2.68% of the population effected.